The specificity of tumour markers in cancer is poor. Indeed, a number of pathophysiological occurrences can induce significant variations of tumour marker plasma concentrations (Touitou & Bogdan, 1988a,b) . The situations resulting in false positive determination have thus to be kept in mind to avoid any misinterpretation in the follow-up of the patients. It has been recently reported that in women, CA 125 plasma concentrations increased during pregnancy (Niloff et al., 1984) and menstruation (Haga et al., 1986; Jager et al., 1988) . Although infrequent, pregnancy (IRMA, CIS) . The assays were performed in the same series to avoid inter-assay variations.
The intra-assay coefficient of variations (n = 30) were as follows: CEA, 7.1% at 3ngml-1; CA-125, 8.7% at 45Uml-P; CA-19.9, 7.1% at 25Uml-'; 3 .5% at 25Uml-1; SCC, 11.3% at 3ngml-1. Statistical analysis was performed using Student's t test (two-tailed).
In the 22 young control women the plasma concentrations of tumour markers at day 2 were all within the normal range except for CA-19.9, which was found abnormally hig1* in three cases (range 43-65 U ml -1). No changes were observed at day 9 when compared to day 2 (Tables I and II) .
In pregnant women the plasma concentrations of the markers were, as a rule, found within the normal range except two slightly elevated SCC (2.3 and 2.5ngml-1) and especially ten CA-19.9 (38-117Uml-1), i.e. for this latter: three cases (9.4%) ranging from 38 to 434Uml-in the first trimester, five cases (15.6%) ranging from 47 to 67 U ml-1 in the second trimester and two cases (5.6%) with values of 71 and 117 U ml-1 in the third trimester of pregnancy. (1.25 and 1.10ngml-P respectively) when compared to the first trimester of pregnancy (0.77ngml-1). The CA-125 determination showed four cases (12.5%) with elevated concentrations in the first trimester of pregnancy, one (3.1 %) in the second trimester and three (8.3%) in the third trimester.
All the tumour markers documented in this report are of common use in monitoring cancers, namely breast (CA-15.3 and CEA), ovarian (CA-125), pancreatic (CA-19.9), colon and rectum cancers ) and squamous cell carcinomas, e.g. uterine cervix (SCC). We report here the effect of menses on the mean plasma concentrations of CA-125 in 10 healthy young women, i.e. a rise' at day 2 (15.4Uml-1) when compared with day 9 (9.7Uml-1). We could thus confirm the results from Pittaway & Fayez (1987) , who reported in nine women an increase from 13 + 3 U ml -1 (days 23-26 of cycle) to 29 + 7 U ml -1 (days 2-4 of cycle) of CA-125 plasma concentrations. However, neither in the women studied by these authors nor in those studied here did this increase reach the cut-off level of 35Uml-1. All the other documented markers were not found modified during menses.
This transverse study on pregnant women allowed us to show that CA-15.3 and SCC plasma concentrations increased significantly during pregnancy although remaining within the normal range. No differences could be seen between the three stages of pregnancy for plasma mean concentrations of the other documented tumour markers (CEA and CA-19.9).
Nevertheless it has to be emphasised that 10% of the studied pregnant women had abnormally high CA-19.9 plasma concentrations (38-117 U ml -1), without any apparent relation to the stage of pregnancy. In the same way, three control women (13.6%), in apparent good health, had abnormally high plasma concentrations of this marker (43-65Uo-.1). CA-19.9 is a poorly specific marker since plasma concentrations have been reported to be increased in a number of non-malignant diseases (Touitou & Bogdan, 1988a) . In the present study we could not attribute the observed increases to any detectable benign pathology. The determination of plasma concentrations of CA-125 in pregnant women confirmed the rise of plasma CA-125 reported in the literature: Nilof et al. (1984) found elevated levels of this marker in six out of 38 women (16%) in the first trimester of pregnancy, whereas Halila et al. (1986) and Pittaway & Fayez (1987) found respectively 11 out of 46 (24%) and three out of 15 women (20%) with increased CA-125 plasma levels, disregarding the stage of pregnancy.
In conclusion, CA-125, CA-15.3 and SCC appear to deserve special attention when documented in pregnant women, and CA-19.9 seems to be very sensitive to benign diseases and care should be given to the interpretation of results of this tumour marker. aTen subjects only.
